Diagnostic tests reported (number of tests)

Product tests sold (number of tests)

Total test volume (number of tests)

Number of sales team representatives (count of representatives)

c150983838bcab8163ff47816709835baf4e4b52ff2e2dbc8bf1dbbf6584a1f8

Cash and Cash Equivalents (USD, thousands)

Short-Term Investments (USD, thousands)

Accounts Receivable (USD, thousands)

Supplies and Inventory (USD, thousands)

Prepaid Expenses and Other Current Assets (USD, thousands)

Total Current Assets (USD, thousands)

Property, Plant and Equipment, Net (USD, thousands)

Right-of-Use Assets, Operating Leases (USD, thousands)

Intangible Assets, Net (USD, thousands)

Goodwill (USD, thousands)

Restricted Cash (USD, thousands)

Other Assets (USD, thousands)

Total Assets (USD, thousands)

Accounts Payable (USD, thousands)

Accrued Liabilities (USD, thousands)

Current Portion of Deferred Revenue (USD, thousands)

Current Portion of Acquisition-Related Contingent Consideration (USD, thousands)

Current Portion of Operating Lease Liabilities (USD, thousands)

Current Portion of Other Liabilities (USD, thousands)

Total Current Liabilities (USD, thousands)

Deferred Tax Liability (USD, thousands)

Acquisition-Related Contingent Consideration, Net of Current Portion (USD, thousands)

Operating Lease Liabilities, Net of Current Portion (USD, thousands)

Other Liabilities (USD, thousands)

Total Liabilities (USD, thousands)

Total Stockholders' Equity (USD, thousands)

Total Liabilities and Stockholders' Equity (USD, thousands)

1c3face263f650edff7dfad8e7771051157dc70420de70bc72a10a0e260e009b

Testing revenue (USD, thousands)

Product revenue (USD, thousands)

Biopharmaceutical and other revenue (USD, thousands)

Total revenue (USD, thousands)

Cost of testing revenue (USD, thousands)

Cost of product revenue (USD, thousands)

Cost of biopharmaceutical and other revenue (USD, thousands)

Intangible asset amortization - cost of revenue (USD, thousands)

Total cost of revenue (USD, thousands)

Gross profit (USD, thousands)

Research and development (USD, thousands)

Selling and marketing (USD, thousands)

General and administrative (USD, thousands)

Impairment of long-lived assets (USD, thousands)

Intangible asset amortization - operating expenses (USD, thousands)

Total operating expenses (USD, thousands)

Income (loss) from operations (USD, thousands)

Other income, net (USD, thousands)

Income (loss) before income taxes (USD, thousands)

Income tax provision (benefit) (USD, thousands)

Net income (loss) (USD, thousands)

Basic earnings (loss) per share (USD)

Diluted earnings (loss) per share (USD)

Shares used to compute basic earnings (loss) per common share (thousands)

Shares used to compute diluted earnings (loss) per common share (thousands)

5a31b56bdef84180c56c321c631d24675707e96f7ab12dccd3cf38b829dc2120

United States

International

Total Revenue

b8a05a43d9d6eb7dfc2c747fb09d9606fd90cc89f24e4622ec2446c1f55913c5

Net income (loss) [USD, thousands]

Depreciation and amortization [USD, thousands]

Loss on disposal of property, plant and equipment [USD, thousands]

Stock-based compensation [USD, thousands]

Deferred income taxes [USD, thousands]

Noncash lease expense [USD, thousands]

Revaluation of acquisition-related contingent consideration [USD, thousands]

Impairment loss [USD, thousands]

Effect of foreign currency on operations [USD, thousands]

Net cash provided by operating activities [USD, thousands]

Purchase of short-term investments [USD, thousands]

Acquisition of C2i, net of cash acquired [USD, thousands]

Purchases of property, plant and equipment [USD, thousands]

Net cash provided by (used in) investing activities [USD, thousands]

Payment of taxes on vested restricted stock units [USD, thousands]

Proceeds from the exercise of common stock options and employee stock purchases [USD, thousands]

Net cash provided by financing activities [USD, thousands]

Effect of foreign currency on cash, cash equivalents and restricted cash [USD, thousands]

Net increase (decrease) in cash, cash equivalents and restricted cash [USD, thousands]

Cash, cash equivalents and restricted cash at beginning of year [USD, thousands]

Cash, cash equivalents and restricted cash at end of year [USD, thousands]

14e2ea545300400799fe1331d0a255bbb268a6fb4214f8f14f15e536f553e91b

Testing Revenue

Product Revenue

Biopharma & Other Revenue

- Biopharma Revenue

- Contract Mfg & Testing

4d758b41d0fc3408fae1f998fa853f827527bd7d09da60b5fbcbab119bdfd8c6

VERACYTE (VCYT)

Financials